Burden of Cervical, Anal, and Oral HPV in an Inner-City Pre-vaccine Adolescent Population

[1]  S. Kjaer,et al.  Trends in incidence of anal cancer and high‐grade anal intraepithelial neoplasia in Denmark, 1978–2008 , 2012, International journal of cancer.

[2]  B. Graubard,et al.  Prevalence of oral HPV infection in the United States, 2009-2010. , 2012, JAMA.

[3]  C. Wheeler,et al.  Impact of an HPV6/11/16/18 L1 virus‐like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection , 2011, International journal of cancer.

[4]  H. Jessen,et al.  HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. , 2011, The New England journal of medicine.

[5]  M. Poljak,et al.  Classification and nomenclature system for human Alphapapillomavirus variants: general features, nucleotide landmarks and assignment of HPV6 and HPV11 isolates to variant lineages. , 2011, Acta dermatovenerologica Alpina, Pannonica, et Adriatica.

[6]  D. Lowy,et al.  Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. , 2011, The Lancet. Oncology.

[7]  D. Lowy,et al.  HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. , 2011, Vaccine.

[8]  C. Wheeler,et al.  Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection , 2009, Human vaccines.

[9]  J. Palefsky,et al.  Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions , 2009, International journal of cancer.

[10]  K. Straif,et al.  A review of human carcinogens--Part B: biological agents. , 2009, The Lancet. Oncology.

[11]  A. Chaturvedi,et al.  Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Daron G Ferris,et al.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. , 2007, The New England journal of medicine.

[13]  F. X. Bosch,et al.  Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions , 2007 .

[14]  C. Wheeler,et al.  Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. , 2006, Vaccine.

[15]  S. Franceschi,et al.  Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis , 2005, The Lancet.

[16]  M. Sherman,et al.  Comparisons of HPV DNA detection by MY09/11 PCR methods , 2002, Journal of medical virology.

[17]  J. Fleiss.  The design and analysis of clinical experiments , 1987 .

[18]  C. Wheeler,et al.  Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.

[19]  Jennifer L. Liang.  National and state vaccination coverage among adolescents aged 13 through 17 years--United States, 2010. , 2011, MMWR. Morbidity and mortality weekly report.